Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Accumulated Expenses (2016 - 2026)

United Therapeutics' Other Accumulated Expenses history spans 17 years, with the latest figure at $72.6 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 22.44% to $72.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.6 million, a 22.44% decrease, with the full-year FY2025 number at $72.6 million, down 22.44% from a year prior.
  • Other Accumulated Expenses hit $72.6 million in Q4 2025 for United Therapeutics, down from $78.3 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for UTHR hit a ceiling of $154.5 million in Q1 2025 and a floor of $24.8 million in Q2 2021.
  • Historically, Other Accumulated Expenses has averaged $63.7 million across 5 years, with a median of $65.4 million in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 47.58% in 2021 and later soared 227.2% in 2024.
  • Tracing UTHR's Other Accumulated Expenses over 5 years: stood at $28.4 million in 2021, then rose by 14.44% to $32.5 million in 2022, then soared by 118.46% to $71.0 million in 2023, then soared by 31.83% to $93.6 million in 2024, then dropped by 22.44% to $72.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for UTHR at $72.6 million in Q4 2025, $78.3 million in Q3 2025, and $95.1 million in Q2 2025.